Ligand Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 58

Market Cap: -

Website

Introduction: Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headqu...

Clinical Trials

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

Phase 2

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Aplindore
Drug: Placebo

First Posted Date: 2008-02-29

Last Posted Date: 2011-10-03

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00626418

Locations: 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸
Clinilabs, Inc., New York, New York, United States
🇺🇸
Sleep Disorders Center of Georgia, Atlanta, Georgia, United States

and more 2 locations

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Phase 2

Completed

Conditions: Early Stage Parkinson's Disease

Interventions: Drug: Placebo
Drug: Aplindore

First Posted Date: 2008-02-26

Last Posted Date: 2011-10-03

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT00623324

Locations: 🇺🇸
Miami Research Associates, Miami, Florida, United States

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: PS433540
Drug: placebo

First Posted Date: 2007-08-30

Last Posted Date: 2011-09-16

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 280

Registration Number: NCT00522925

Locations: 🇺🇸
Westlake Medical Center, Westlake Village, California, United States
🇺🇸
Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States

and more 12 locations

Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: MB07803
Drug: Placebo

First Posted Date: 2007-04-09

Last Posted Date: 2011-10-03

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT00458016

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: raloxifene
Drug: lasofoxifene
Drug: Placebo

First Posted Date: 2005-09-13

Last Posted Date: 2011-08-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT00163137

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: Lasofoxifene
Drug: Placebo

First Posted Date: 2005-09-02

Last Posted Date: 2011-08-10

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 497

Registration Number: NCT00143273

Locations: Pfizer Investigational Site

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Other: placebo
Drug: lasofoxifene

First Posted Date: 2005-09-01

Last Posted Date: 2011-08-15

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 8556

Registration Number: NCT00141323

Locations: 🇬🇧
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom

Bexarotene in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-05-25

Last Posted Date: 2013-05-30

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT00003752

Locations: 🇺🇸
Baptist Regional Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States
🇺🇸
Louisiana State University School of Medicine, New Orleans, Louisiana, United States

and more 27 locations

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Phase 2

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Lymphoma

First Posted Date: 2004-03-25

Last Posted Date: 2013-05-30

Lead Sponsor: Ligand Pharmaceuticals

Registration Number: NCT00006345

Locations: 🇺🇸
Veterans Affairs Medical Center - Miami, Miami, Florida, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Rush Cancer Institute, Chicago, Illinois, United States

and more 8 locations

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: MB07133 300mg/m2/day
Drug: MB07133 600 mg/m2/day
Drug: MB07133 1200 mg/m2/day
Drug: MB07133 1800 mg/m2/day
Drug: MB07133 2400 mg/m2/day

First Posted Date: 2003-12-05

Last Posted Date: 2011-08-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT00073736

Locations: 🇺🇸
University of California at Irvine, Orange, California, United States
🇨🇳
Tri-Services General Hospital, Taipei, Nei Hu District, Taiwan
🇨🇳
Chang-Gung Memorial Hospital, Taipei, Taoyuan County, Taiwan

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy